On December 23, Walvax Bio(300142) issued an announcement stating that its subsidiary participated in the National Immunization Program's centralized procurement project for vaccines and successfully entered the shortlist. The announcement shows that Yuxi Zerun Biotechnology Co., Ltd.'s bivalent human papillomavirus vaccine (Pichia pastoris) was shortlisted for the project, with a shortlisted unit price of 27.5 yuan.

This vaccine is primarily used to prevent diseases caused by high-risk HPV types 16 and 18, including cervical cancer. It was launched in China in 2022 and received prequalification from the World Health Organization in August 2024. This inclusion in the list will help expand the company's sales of its bivalent HPV vaccine, increase market coverage, promote the market development of related products, and enhance brand influence.

However, the announcement also pointed out that since only two companies were shortlisted, further negotiations with various provinces are needed, and the implementation period for vaccination is relatively long. Therefore, the impact on the company's short-term operating performance will not be significant. Furthermore, there are still uncertainties regarding the final signing of procurement contracts, production and supply schedules, and the actual number of vaccinations.

In the first three quarters of 2025, Walvax Bio achieved revenue of RMB 1.719 billion and net profit attributable to the parent company of RMB 163 million.

https://finance.eastmoney.com/a/202512233599687656.html